Adverse Event Reporting in Pharmacovigilance
Adverse Event Reporting in Pharmacovigilance:
What you need to know
Pharmacovigilance, the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems, plays a vital role in ensuring patient safety and the effectiveness of medical treatments. A critical aspect of pharmacovigilance is the timely and accurate reporting of adverse events (AEs).
• What is an Adverse Event?
Any drug that is developed, manufactured, and marketed for sale, when given at therapeutic dose level may also cause some undesirable effect(s) along with its benefits. These undesirable effects are referred to as adverse effects. An adverse event/adverse experience (AE) may not necessarily be an adverse drug reaction (ADR) unless checked for its causality using various causality assessment scales
In pharmacovigilance, adverse event reporting is crucial for identifying potential safety concerns, understanding the risks and benefits of medications, and taking appropriate regulatory actions to protect public health. It involves collecting and analyzing information on adverse events from various sources, such as healthcare professionals, patients, regulatory authorities, and clinical studies.
• The Purpose of Adverse Event Reporting: The primary objective of adverse event reporting is to detect and assess any potential risks associated with pharmaceutical products. By systematically documenting and analyzing adverse events, regulatory authorities and pharmaceutical companies can identify safety concerns, take appropriate measures to mitigate risks and safeguard the well-being of patients.
• The Role of Healthcare Professionals: Healthcare professionals, such as physicians, nurses, and pharmacists, play a critical role in identifying and reporting adverse events. They are at the forefront of patient care and have direct interactions with patients, making them well-positioned to observe and document any unexpected or harmful effects of medications. Timely and accurate reporting by healthcare professionals contributes significantly to the overall safety profile of drugs and medical devices.
An adverse event is any undesirable experience associated with the use of a medical product in a patient.
The event is serious and should be reported to FDA when the patient outcome is:
Death: Report if you suspect that the death was an outcome of the adverse event, and include the date if known.
Life-threatening: Report if suspected that the patient was at substantial risk of dying at the time of the adverse event, or use or continued use of the device or other medical product might have resulted in the death of the patient.Hospitalization (initial or prolonged): Report if admission to the hospital or prolongation of hospitalization was a result of the adverse event. Emergency room visits that do not result in admission to the hospital should be evaluated for one of the other serious outcomes (e.g., life-threatening; required intervention to prevent permanent impairment or damage; other serious medically important event).
Disability or Permanent Damage: Report if the adverse event resulted in a substantial disruption of a person's ability to conduct normal life functions, i.e., the adverse event resulted in a significant, persistent or permanent change, impairment, damage or disruption in the patient's body function/structure, physical activities and/or quality of life.
Congenital Anomaly/Birth Defect: Report if you suspect that exposure to a medical product prior to conception or during pregnancy may have resulted in an adverse outcome in the child.
Required Intervention to Prevent Permanent Impairment or Damage (Devices): Report if you believe that medical or surgical intervention was necessary to preclude permanent impairment of a body function, or prevent permanent damage to a body structure, either situation suspected to be due to the use of a medical product.
Other Serious (Important Medical Events): Report when the event does not fit the other outcomes, but the event may jeopardize the patient and may require medical or surgical intervention (treatment) to prevent one of the other outcomes. Examples include allergic bronchospasm (a serious problem with breathing) requiring treatment in an emergency room, serious blood dyscrasias (blood disorders) or seizures/convulsions that do not result in hospitalization. The development of drug dependence or drug abuse would also be examples of important medical events.
• Why to Report an Adverse Event:
Reporting adverse events isn't just about patient safety. It also helps protect healthcare organizations from costly liability claims and financial losses caused by reduced reimbursement for the treatment of preventable conditions acquired while in hospital care.
• How Adverse Events are Reported:
Figure – 1.1 General overview of the steps involved in adverse event reporting:
Identification: Adverse events are identified through spontaneous reporting by healthcare professionals, patients, or other sources. This can also include signals from clinical trials, epidemiological studies or other research.
Reporting: The identified adverse events are reported to the appropriate regulatory authority or the marketing authorization holder (MAH). This can be done using specific reporting forms, electronic systems, or other established channels.
Collection and Documentation: The reported adverse events are collected and documented in a systematic manner. This includes information such as the patient's demographic details, medical history, concomitant medications, details of the adverse event, and its severity.
Assessment: The reported adverse events are assessed by pharmacovigilance experts to determine the causality between the medication and the event. This involves evaluating the available evidence, considering factors like temporal relationship, dose-response relationship, challenge /rechallenge, and alternative explanations.
Signal Detection: The assessed adverse events are analyzed to identify potential safety signals or patterns. Statistical methods, data mining, and other signal detection techniques are used to identify any new or previously unrecognized safety concerns.
Evaluation and Decision-making: The safety signals and collected data are evaluated to determine the significance and potential impact on public health. Regulatory authorities or the MAH make decisions regarding labeling changes, contraindications, warnings, or other regulatory actions based on the assessment.
Communication: The findings and decisions are communicated to healthcare professionals, patients, and the public through various channels, such as drug safety alerts, product labeling updates, public health advisories, or educational materials.
This are the steps involved in adverse event reporting within the field of pharmacovigilance. However, specific reporting processes may vary depending on the country, regulatory authority, or healthcare system involved.
Figure – 1.2 Adverse event process flow chart
• What to Report?
• Patient Identifier: Who experienced AE?
- Verification of the existence of a patient (e.g. sex, age, etc.)
• Event description: What was AE? The nature of the AE, any sign/symptoms & outcome.
• Reporter: Who is Reporting AE?
- Give your name, address and phone number as you may need to be contacted for further information.
- If you are reporting on behalf of a healthcare professional (e.g. if you are a sales representative) be prepared to also give their details.
• Drug: What product was taken by patient?- Name of product taken by patient.
• Submitting Adverse Event Reports to FDA:
• The Importance of Adverse Event Reporting:
Early Detection of Safety Signals: AE reporting serves as an early warning system for identifying potential safety concerns associated with medications. By reporting AEs, healthcare professionals, patients, and other stakeholders contribute to the accumulation of data necessary for monitoring drug safety. Detecting safety signals promptly allows regulatory authorities and pharmaceutical companies to take appropriate actions, such as issuing warnings, updating product labels, or even recalling drugs from the market, to protect public health.
Assessment of Benefit-Risk Profile: AE reports provide valuable data that helps regulatory authorities and healthcare professionals evaluate the benefit-risk profile of a medication. This assessment is crucial for determining whether the potential benefits of a drug outweigh its potential risks.
Post-Marketing Surveillance: Clinical trials provide valuable safety data, but they have limitations due to their controlled nature and limited sample sizes. This post-marketing surveillance helps identify rare or delayed AEs that may not have been detected during clinical trials.
Patient Empowerment: Encouraging patients to report AEs enhances patient engagement and empowerment in their own healthcare. Patients are the ultimate end-users of medications, and their firsthand experiences provide unique insights into drug safety. By actively involving patients in adverse event reporting, healthcare systems can promote patient-centered care and strengthen the patient-provider relationship.
Continuous Improvement: Adverse event reporting facilitates a feedback loop between healthcare professionals, patients, and regulatory authorities, fostering continuous improvement in drug safety. Reporting AEs allows for the identification of patterns, trends, or recurring issues associated with specific medications.
• Conclusion:
Adverse event reporting is a fundamental pillar of pharmacovigilance that ensures patient safety by identifying and addressing potential risks associated with pharmaceutical products. The active participation of healthcare professionals, patients and other stakeholders is essential for a robust reporting system. By continuously improving the reporting process and leveraging advanced data analysis techniques, we can enhance pharmacovigilance efforts and safeguard public health. Remember, reporting adverse events not only benefits individual patients but also contributes to the collective knowledge that shapes the future of healthcare.
Comments